DCSIMG

New €7.2m investment a huge boost to Tipperary health plant

The Merck Sharp & Dohme plant at Ballydine.

The Merck Sharp & Dohme plant at Ballydine.

MSD has invested €7.2 million in its Tipperary plant that will play a key role in the production of new medicines on site.

The plant at Ballydine, between Clonmel and Carrick-on-Suir, has been identified by the parent company as a crucial compoment of medicine production.

It said the investment focussed on enhancing a number of areas that will support the site’s central position in the development and launch of many of the company’s newest medicines.

In recent years the site has made many positive advances, with the construction in 2010 of a €100 million formulation and research and development (R&D) facility.

Thanks to this investment the site has the capability to work on the development of new medicines that are critical to the MSD global pipeline and have the potential to enhance the lives of millions of patients worldwide. Fifteen new innovative medicines are currently in development at the site to treat patients with conditions such as HIV, Diabetes, Osteoporosis, and Hepatitis C.

With increasing demand for MSD’s products worldwide, the Ballydine facility has become an important part of the company’s global operations and has been designated as the main site globally for the development of new pipeline medicines. It has successfully manufactured medicines for a wide range of diseases for over 38 years and currently employs over 400 people.

The €7.2m investment will support the ongoing development of the site and will ultimately bring new medicines to patients across the world more quickly. It will be used to further increase the site’s capability to work on the different stages of the development and manufacturing for current and future medicines with the installation of new equipment as well as improving reliability and sustainability on site with the replacement of 2.5kms of pipework.

MSD in Ballydine was established in 1976 and currently exports to over 30 countries with main markets being Europe, USA and Japan. The site has long recognised the importance of the relationships it has with the local community and partners with a number of local organisations, schools and charities each year

 

Comments

 
 

Back to the top of the page